Advertisement

Synthesis and molecular docking studies of novel pyrimidine derivatives as potential antibacterial agents

  • Xue-Qian Bai
  • Chun-Shi Li
  • Ming-Yue Cui
  • Ze-Wen Song
  • Xing-Yu Zhou
  • Chao Zhang
  • Yang Zhao
  • Tian-Yi ZhangEmail author
  • Tie-Yan JiangEmail author
Original Article
  • 27 Downloads

Abstract

The present work describes the in vitro antibacterial evaluation of some new pyrimidine derivatives. Twenty-two target compounds were designed, synthesized and preliminarily explored for their antimicrobial activities. The antimicrobial assay revealed that some target compounds exhibited significantly inhibitory efficiencies toward bacteria and fungal including drug-resistant pathogens. Compound 7c presented the most potent inhibitory activities against Gram-positive bacteria (e.g., Staphylococcus aureus 4220), Gram-negative bacteria (e.g., Escherichia coli 1924) and the fungus Candida albicans 7535, with an MIC of 2.4 μmol/L. Compound 7c was also the most potent, with MICs of 2.4 or 4.8 μmol/L against four multidrug-resistant, Gram-positive bacterial strains. The toxicity evaluation of the compounds 7c, 10a, 19d and 26b was assessed in human normal liver cells (L02 cells). Molecular docking simulation and analysis suggested that compound 7c has a good interaction with the active cavities of dihydrofolate reductase (DHFR). In vitro enzyme study implied that compound 7c also displayed DHFR inhibition.

Graphic abstract

Keywords

Pyrimidine Antibacterial activity Toxicity Molecular docking DHFR inhibition 

Notes

Acknowledgements

This work was supported by the Doctoral Foundation of Jilin Medical University (No. JYBS2018007), the Health Department of Jilin Province (2018ZC034) and the Department of Education of Jilin Province (No. JJKH20191070KJ).

References

  1. 1.
    Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122–S129CrossRefGoogle Scholar
  2. 2.
    Bi Y, Liu XX, Zhang HY, Yang X, Liu ZY, Lu J, Lewis PJ, Wang CZ, Xu JY, Meng QG, Ma C, Yuan CS (2017) Synthesis and antibacterial evaluation of novel 3-substituted ocotillol-type derivatives as leads. Molecules 22:E590CrossRefGoogle Scholar
  3. 3.
    Carrel M, Perencevich EN, David MZ (2015) USA300 methicillin-resistant Staphylococcus aureus, United States, 2000–2013. Emerg Infect Dis 21:1973–1980CrossRefGoogle Scholar
  4. 4.
    Hvistendahl M (2012) Public health. China takes aim at rampant antibiotic resistance. Science 336:795CrossRefGoogle Scholar
  5. 5.
    Yezli S, Li H (2012) Antibiotic resistance amongst healthcare-associated pathogens in China. Int J Antimicrob Agents 40:389–397CrossRefGoogle Scholar
  6. 6.
    Azeredo da Silveira S, Perez A (2015) Liposomes as novel anti-infectives targeting bacterial virulence factors? Expert Rev Anti Infect Ther 13:531–533CrossRefGoogle Scholar
  7. 7.
    Taylor PW, Stapleton PD, Paul Luzio J (2002) New ways to treat bacterial infections. Drug Discov Today 7:1086–1091CrossRefGoogle Scholar
  8. 8.
    O’Neill J (2016) Review on antimicrobial resistance, Government of the UK. http://apo.org.au/node/63983
  9. 9.
    Wirnsberger G, Zwolanek F, Asaoka T, Kozieradzki I, Tortola L, Wimmer RA, Kavirayani A, Fresser F, Baier G, Langdon WY, Ikeda F, Kuchler K, Penninger JM (2016) Inhibition of CBLB protects from lethal Candida albicans sepsis. Nat Med 22:915–923CrossRefGoogle Scholar
  10. 10.
    Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163CrossRefGoogle Scholar
  11. 11.
    Denning DW, Bromley MJ (2015) How to bolster the antifungal pipeline. Science 347:1414–1416CrossRefGoogle Scholar
  12. 12.
    Brown GD, Denning DW, Levitz SM (2012) Tackling human fungal infections. Science 336:647CrossRefGoogle Scholar
  13. 13.
    Khalafi-Nezhad A, Soltani Rad MN, Mohabatkar H, Asrari Z, Hemmateenejad B (2005) Design, synthesis, antibacterial and QSAR studies of benzimidazole and imidazole chloroaryloxyalkyl derivatives. Bioorg Med Chem 13:1931–1938CrossRefGoogle Scholar
  14. 14.
    Seenaiah D, Reddy PR, Reddy GM, Padmaja A, Padmavathi V, Krishna NS (2014) Synthesis, antimicrobial and cytotoxic activities of pyrimidinyl benzoxazole, benzothiazole and benzimidazole. Eur J Med Chem 77:1–7CrossRefGoogle Scholar
  15. 15.
    Desai NC, Kotadiya GM, Trivedi AR (2014) Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs. Bioorg Med Chem Lett 24:3126–3130CrossRefGoogle Scholar
  16. 16.
    Jin X, Zheng CJ, Song MX, Wu Y, Sun LP, Li YJ, Yu LJ, Piao HR (2012) Synthesis and antimicrobial evaluation of l-phenylalanine-derived C5-substituted rhodanine and chalcone derivatives containing thiobarbituric acid or 2-thioxo-4-thiazolidinone. Eur J Med Chem 56:203–209CrossRefGoogle Scholar
  17. 17.
    Zhang TY, Li C, Li YR, Li XZ, Sun LP, Zheng CJ, Piao HR (2016) Synthesis and antimicrobial evaluation of aminoguanidine and 3-amino-1,2,4-triazole derivatives as potential antibacterial agents. Lett Drug Des Discov 13:1063–1075CrossRefGoogle Scholar
  18. 18.
    Davari AS, Abnous K, Mehri S, Ghandadi M, Hadizadeh F (2014) Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors. Bioorg Chem 57:83–89CrossRefGoogle Scholar
  19. 19.
    Seleem MA, Disouky AM, Mohammad H, Abdelghany TM, Mancy AS, Bayoumi SA, Elshafeey A, El-Morsy A, Seleem MN, Mayhoub AS (2016) Second-generation phenylthiazole antibiotics with enhanced pharmacokinetic properties. J Med Chem 59:4900–4912CrossRefGoogle Scholar
  20. 20.
    Eldehna WM, Altoukhy A, Mahrous H, Abdel-Aziz HA (2015) Design, synthesis and QSAR study of certain isatin-pyridine hybrids as potential anti-proliferative agents. Eur J Med Chem 90:684–694CrossRefGoogle Scholar
  21. 21.
    Li B, Pai R, Di M, Aiello D, Barnes MH, Butler MM, Tashjian TF, Peet NP, Bowlin TL, Moir DT (2012) Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities. J Med Chem 55:10896–10908CrossRefGoogle Scholar
  22. 22.
    Lam T, Hilgers MT, Cunningham ML, Kwan BP, Nelson KJ (2014) Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines. J Med Chem 57:651–668CrossRefGoogle Scholar
  23. 23.
    Oefner C, Bandera M, Haldimann A, Laue H, Schulz H (2009) Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother 63:687–698CrossRefGoogle Scholar
  24. 24.
    Zhang TY, Zheng CJ, Wu J, Sun LP, Piao HR (2019) Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. Bioorg Med Chem Lett 29:1079–1084CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Xue-Qian Bai
    • 1
  • Chun-Shi Li
    • 2
  • Ming-Yue Cui
    • 2
  • Ze-Wen Song
    • 1
    • 3
  • Xing-Yu Zhou
    • 1
  • Chao Zhang
    • 1
  • Yang Zhao
    • 1
  • Tian-Yi Zhang
    • 1
    Email author
  • Tie-Yan Jiang
    • 4
    Email author
  1. 1.Jilin Medical UniversityJilinPeople’s Republic of China
  2. 2.The Third People’s Hospital of DalianDalianPeople’s Republic of China
  3. 3.Department of PharmaryYanbian UniversityYanjiPeople’s Republic of China
  4. 4.Changning Branch of Shanghai Municipal Public Security BureauShanghaiPeople’s Republic of China

Personalised recommendations